Breast Cancer

Updated results from the pivotal phase 3 BOLERO-2 trial uphold, and even add to, the previous benefits reported for the addition of everolimus to exemestane in advanced breast cancer, including a positive effect on bone markers.1,2
In women with metastatic breast cancer, less frequent dosing of zoledronic acid (ZA) may be as protective as the standard monthly infusion, according to 2 studies presented at the 2012 Annual Meeting of the American Society of Clinical Oncology (ASCO).
Adverse events (AEs) related to chemotherapy for metastatic breast cancer (MBC) create a substantial economic burden that is primarily explained by increased inpatient, outpatient, and pharmacy costs, said Sara A. Hurvitz, MD, of the University of California Los Angeles, who presented an economic analysis at the 2012 Annual Meeting of the American Society of Clinical Oncology.
According to an analysis of the Eastern Cooperative Oncology Group trial ECOG-E1199 by Schneider and colleagues, the development of grade 2 to 4 peripheral neuropathy in patients with operable breast cancer who received taxanes does not appear to affect clinical outcome.1

The biggest newsmaker at the 2012 Annual Meeting of the American Society of Clinical Oncology (ASCO) was a compound whose name and actions sound practically missilelike: T-DM1. Because of its highly targeted and potent effect that spares surrounding healthy tissue, T-DM1 not only has potent antitumor effects but is also very well tolerated.

The biggest newsmaker at the 2012 Annual Meeting of the American Society of Clinical Oncology (ASCO) was a compound whose name and actions sound practically missile-like: T-DM1. Because of its highly targeted and potent effect that spares surrounding healthy tissue, T-DM1 not only has potent antitumor effects but is also very well tolerated.

Updated results of the phase 3 BOLERO-2 trial demonstrated that adding everolimus to hormonal therapy extends progression-free survival (PFS) in hormone receptor–positive (HR+) metastatic breast cancer that progressed on hormonal therapy with anastrozole or letrozole. The positive outcomes observed in this study suggest that everolimus plus exemestane will be a new option for postmenopausal metastatic HR+ breast cancer.

A quality-of-life analysis of the large randomized NCIC MA. 27 trial shows that symptoms of endocrine therapy can be severe and have a negative effect on quality of life. The study also found that women with side effects from previous chemotherapy or radiotherapy before they start taking endocrine therapy are at higher risk for early discontinuation.

Updated results of the phase 3 BOLERO-2 trial demonstrated that adding everolimus to hormonal therapy extends progression-free survival (PFS) in hormone receptor–positive (HR+) metastatic breast cancer that progressed on hormonal therapy with anastrozole or letrozole. The positive outcomes observed in this study suggest that everolimus plus exemestane will be a new option for postmenopausal metastatic HR+ breast cancer.

In a randomized phase 2 study of metastatic breast cancer patients, peripheral neuropathy (PN) was less likely to occur in patients receiving eribulin mesylate than with ixabepilone.

“Peripheral neuropathy is a big problem in the treatment of breast cancer. Across the spectrum, patients have it, and we don’t know how to treat it,” said Linda T. Vahdat, MD, of Weill Cornell Medical College in New York, who presented the study at the 2011 CTRC-AACR San Antonio Breast Cancer Symposium (Poster P5-19-02).

Page 12 of 18
Results 111 - 120 of 171